Catalyst Event
Eli Lilly and Co (LLY) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
5/28/2026, 12:00:00 AM
Announced that CVS Caremark will restore preferred formulary coverage for its weight-loss drug Zepbound effective October 1, 2026, and add its oral drug Foundayo effective June 1, 2026, significantly expanding patient access. High importance is estimated due to the expected >10% price impact from increased market reach.
Korean Translation
CVS 케어마크가 체중 감량 치료제 제파운드에 대한 보험 등재를 2026년 10월 1일부터 복원하고, 경구용 치료제 파운다요를 2026년 6월 1일부터 추가할 것이라고 발표하여 환자 접근성이 크게 확대됨. 시장 점유율 확대에 따른 10% 이상의 주가 영향이 예상되어 중요도를 'High'로 설정함.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q2 2026 earnings release and conference call. Medium importance is estimated as earnings releases typically cause >5% price volatility scheduled.
8/5/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
The Q2 2026 earnings release scheduled for 2026-07-29, for which high importance is estimated due to typical market volatility surrounding quarterly results, is expected.
7/29/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Q2 2026 earnings release is scheduled for July 16, 2026; a price impact of at least 5% is estimated based on historical volatility, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Final dividend of HKD 0.20 per share ex-dividend on July 3, 2026; standard corporate action with minor price adjustment scheduled.
7/3/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Other
Ex-dividend date for the 2025 final dividend of HK$0.15 per share, which was announced on March 25, 2026. The payment date is July 15, 2026.
6/24/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Other
Ex-dividend date (2026-06-19) for a proposed record-high annual dividend of CHF 4.70 per share; impact estimated at ~2% as dividend is record-high, scheduled.
6/19/2026, 12:00:00 AM